Two of the point-counterpoint sessions held at the recent AUA meeting in Dallas focused on two prominent discussion topics in benign prostatic hyperplasia (BPH) and prostate cancer. Summaries of these sessions are presented below.
BPH: Intervention or pharmacologic therapy
The use of pharmacologic therapy vs interventional strategies for BPH was debated; the moderator was Dr P Walsh (USA). Dr JD McConnell (USA) presented the case for pharmacologic therapy. He pointed out that medical therapy can target speci®c aspects of the disease, such as hyperplasia or symptoms. One of the two main medical therapies, a-blockers, can reduce symptom scores by around 40% and improve maximum¯ow rates by 30±35%. The HYCAT Study also showed that transurethral resection of the prostate (TURP) procedures could be reduced with the use of the a-blocker, terazosin. a-blockers are generally well-tolerated, and, importantly, unlike interventional therapy, side-effects can be reversed on discontinuation of treatment. The other major medical option is ®nasteride, a 5a-reductase inhibitor. Again, ®nasteride use results in improvement in symptoms (20±30%) and maximum¯ow rates (20%), the effects being greater in men with prostates greater than 40 ml. In addition, the Proscar Long-Term Ef®cacy and safety Study (PLESS) showed that ®nasteride can reduce the long-term complications of BPH, that is the need for BPHrelated surgery and acute urinary retention. The main side-effects of ®nasteride are sexually-related and although these tend to occur on 10±15% of men, only about 4% of men discontinue treatment for this reason. It was Dr McConnell's opinion that although interventional therapy provides a greater degree of symptom relief than pharmacologic therapy, such bene®ts must be balanced against the obvious risks of surgery.
Dr TR Malloy (USA) presented the case for interventional therapy. He suggested that careful monitoring of medical therapy is necessary, with interventional therapy used in the following situations:
worsening symptoms despite increased drug usage; recurrent urinary tract infection (UTI) or haematuria; poor patient compliance; upper tract deterioration.
Surgery is the established ®rst option in patients with urinary retention, bladder stones, renal failure, recurrent UTI or haematuria. Although medical therapy is a simpler treatment option and may be preferred by patients, this needs to be balanced against effective care. The TURP procedure has been modi®ed in recent years to limit nerve damage and, in addition, a whole range of newer procedures have been developed, including hypothermia, laser therapy, transurethral needle ablation (TUNA), ultrasound, stents and electrovaporisation. Medical therapy should be used with care and conditions identi®ed prior to treatment that may reduce its effectiveness, for example the presence of a large middle lobe. Costs are also an important issue, and several years of therapy with a combination of drugs may be needed, which makes it more expensive than the TURP procedure.
A number of case studies were presented at the end of the debate with discussion on how these could be most appropriately managed.
Localized prostate cancer: External beam vs brachytherapy
The use of external beam irradiation vs brachytherapy in the treatment of localized prostate cancer was debated. The moderator was Dr P Schellhammer (USA). Dr G Hanks (USA) presented the case for 3-D conformal radiotherapy. He pointed out that radiation can be delivered according to the shape of the prostate and good survival rates can be achieved with this technique. Patients with stage T1/2 disease, Gleason grade 6 and prostate-speci®c antigen (PSA) level`10 ng/ml have a 90% chance of cure with doses of 71±72 Gy; increased doses are needed for patients with a poorer prognosis. Global quality of life is improved and bowel and urinary function are at similar levels as untreated patients. A comparison of data show that similar levels of urinary continence can be achieved with external beam irradiation and brachytherapy.
Dr J Blasko (USA) proposed that brachytherapy was advantageous for a number of reasons, including the fact that it is convenient to use and can be administered on an outpatient basis. Importantly, brachytherapy can achieve higher intraprostatic doses than external beam irradiation and progression-free survival in T1/2 patients is long. Other points raised during the session included the agreement that a comparative trial of the two forms of radiation would be dif®cult to conduct. Also, the effects of both therapies appear to be durable, but if salvage therapy were needed, it should take the form of hormonal therapy and not further radiotherapy due to associated increased morbidity.
Suggestions, comments and news can be sent to tprinz @urology.medsch.ucla.edu in the of®ce of Arie Belldegrun, MD, Department of Urology, UCLA School of Medicine.
Two case histories were presented by Dr Schellhammer and the panellists asked to comment on what treatment should be applied.
Case 1: Stage T1c, PSA`10 ng/ml, Gleason score 3 3, bilobar cancer with 50% involvement in one core from each lobe. Life expectancy b 15 y; no comorbidities. It was agreed that 3D conformal radiotherapy or brachytherapy was appropriate.
Case 2: Stage T1c, Gleason score 3 4 or even 8, PSÀ 10 ng/ml. Life expectancy b 15 y; no co-morbidities. Dr Hanks suggested dose escalation of external beam radiation to 77±78 Gy; care should be taken to irradiate all of the prostate. External beam radiotherapy with brachytherapy as a boost was suggested by Dr Blasko to be the option most people would use. In his opinion, brachytherapy was not suitable as de®nitive data were not available on the penetrative capabilities of interstitial seed radiotherapy.
Prostate cancer prevention
The National Cancer Institute (NCI) has set up several task forces, including a Prevention Review Group and the Prostate Cancer Progress Review Group (PRG), to review the research on prostate cancer being supported by the NCI. In 1997, the NCI sponsored approximately 500 projects in this area totalling over $87 million. Prostate cancer prevention studies include the ongoing Prostate, Lung, Colon, Ovary (PLCO) randomized screening/intervention trial, which will enrol 75 000 individuals over a 10 y period. The Finasteride Prostate Cancer Prevention Trial (PCPT-1) has also enrolled over 18 000 asymptomatic men over 55 y of age and will follow subjects for 7 y. Several randomized, placebo-controlled chemoprevention trials in cohorts with high-grade prostatic intraepithelial neoplasia will be conducted. Two trials that have been initiated include an evaluation of androgen deprivation therapy (¯utamide), which will enrol 200 patients at the Mayo Clinic/NCCTG. The second trial by the SouthWestern Oncology Group will look at selenium supplementation and will enrol 450 patients.
Two important NCI sponsored prevention trials completed and published between 1996 and 1998 studied the effects of vitamin E (in 29 000 Finnish smokers) (Heinonen OP et al JNCI 1998; 90: 440 ± 446) and selenium (in 1300 US high-risk individuals) (Clark LC et al JAMA 1996; 276: 1957±1963) . Signi®cant reductions in prostate cancer incidence and mortality were observed in both studies.
Further information on the recommendations of the PRG will be included in the next issue of Hot News.
Center for prostate disease research (CPDR)
The CPDR was set up in 1992 with funding derived from the United States Congress. Dr (Lieutenant Colonel) Moul is director of the CPDR research programme, which has three broad aims: The development of a tri-service Multicenter National Prostate Cancer Longitudinal Database. The CPDR will conduct basic and clinical research programmes on the prostate. Objectives will be to improve early detection and prognostic factors and to develop potential treatment of prostate disease. The natural history of prostate disease, outcomes research and behavioural, psychosocial and quality of life issues as they relate to the prostate will also be addressed.
Prostate cancer survival rates
Two studies have recently been published looking at PSA levels post-radical prostatectomy and prior to radiotherapy. Dr Patrick Walsh and colleagues at the Johns Hopkins, Baltimore, USA looked at 1997 men who underwent radical prostatectomy between 1982 and 1997 (Pound CR et al JAMA 1999 281: 1591±1597) . Their aim was to determine whether PSA levels of 2 ng/ml and over were detectable after surgery, which would indicate biochemical recurrence, and, if so, how long did it take the cancer to progress to an advanced stage. Results showed that 82% of men were free of cancer at 15 y post-surgery. A total of 315 (15%) of men had elevated PSA levels; 103 (34%) of these men developed metastases within the study period, suggesting that a rising PSA level is not always indicative of a poor outcome. Once men developed metastatic disease, the median actuarial time to death was 5 y. It appears that the time interval between surgery and the appearance of metastatic disease was predictive of time until death.
The second study looked at whether PSA level at initial diagnosis of prostate cancer can be used to estimate the probability of cancer-free survival after radiation treatment (Shipley WU et al. JAMA 1999; 281: 1598±15604) . Pooled records from six medical centres of 1765 patients with localized prostate cancer showed that higher initial PSA levels meant a poorer outcome. Men presenting with a PSA level`9.2 ng/ml, 9.2±19.7 ng/ml, b 19.7 ng/ml (Gleason score 2±6) and b 19.7 ng/ml (Gleason score 7± 10) had 5 y progression free survival rates of 81%, 69%, 47% and 29%, respectively. The 5 y estimates of overall survival and disease-speci®c survival were high at 85% and 95.1%, respectively. It should be noted that about 60 000 of the 180 000 men diagnosed in 1999 in the US with prostate cancer will undergo radiation therapy.
